The subsequent evaluation of RO5126766 in solid tumors or multiple myeloma (12 NSCLC, five gynecological malignancy, four colorectal cancer, one melanoma, and seven multiple myeloma) with RAS–RAF–MEK pathway mutations showed that 7 of 26 evaluable patients achieved objective responses [143]. This evidence concerns the gene MAP2K7 and colorectal cancer.